Montelukast Sandoz (Montelukast)

Montelukast blocks the cysteinyl leukotriene receptor CysLT1, stopping leukotrienes from binding. This inhibition reduces bronchoconstriction, mucus production, and airway inflammation, leading to improved breathing and fewer allergic nasal symptoms.

The specific dose and dosing schedule of Montelukast Sandoz are determined by the prescribing clinician based on the patient’s age, condition severity, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for Montelukast in pregnancy are limited, and the product is classified as pregnancy category unknown. It should only be used if the potential benefit justifies any potential risk to the fetus. Caution is also advised during breastfeeding, and a healthcare professional should evaluate the risk‑benefit ratio.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs), and required import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting beta‑agonists. It is particularly useful for patients who cannot tolerate inhaled steroids or who need additional control of allergic rhinitis. Its mechanism differs from bronchodilators, targeting inflammatory pathways rather than immediate airway relaxation.

Montelukast Sandoz tablets should be stored at ambient temperature below 25 °C. Keep them in the original container, protect from moisture and direct sunlight, and ensure they are out of reach of children.

Montelukast Sandoz is taken orally, usually as a whole tablet with or without food. The tablet should be swallowed whole with a glass of water and not chewed or crushed, unless otherwise directed by a healthcare professional.

Serious risks include severe allergic reactions such as rash, angioedema, or anaphylaxis, as well as neuropsychiatric events like depression, anxiety, or suicidal thoughts. Rarely, liver enzyme elevations and severe skin reactions (e.g., Stevens‑Johnson syndrome) have been reported. Patients should seek immediate medical attention if any of these occur.

Montelukast Sandoz should be avoided in individuals with a known hypersensitivity to montelukast or any tablet excipients. Caution is advised for patients with severe hepatic impairment, active psychiatric disorders, or those taking interacting medications listed under major interactions.